No Data
No Data
At the 5th RAS Initiative Symposium in 2024, Akeso-B (01167.HK) presented preclinical data on the combination of SHP2 inhibitor JAB-3312 and KRAS G12C inhibitor lorlatinib.
Grain 10 released on October 9th. Acosta-B (01167.HK) announced that the company presented preclinical data on the combined use of SHP2 inhibitor JAB-3312 and KRAS G12C inhibitor Gorarelec inhibitor in the form of a poster at the Fifth RAS Initiative Symposium 2024. The data demonstrates that Gorarelec and JAB-3312 show strong anti-tumor effects in both in vitro and in vivo experiments, with JAB-3312 enhancing the anti-tumor effects of Gorarelec.
Gaxo-B (01167) spent 0.197 million Hong Kong dollars to repurchase 0.1002 million shares on October 8th.
Jardine Matheson Group-B (01167) announced, on October 8, 2024, spending 0.197 million Hong Kong dollars to repurchase 10...
Jacobio Pharmaceuticals Group Insider Purchases Yet To Pay Off Regardless Of Recent Strength
Jaccoo-B (01167) will showcase the clinical data of the BET inhibitor JAB-8263 at the 66th American Society of Hematology Annual Meeting in 2024.
Kaska-B (01167) announced that the company will participate in the 66th American Society of Hematology (ASH) in 2024...
JACOBIO-B: 2024 INTERIM REPORT
Jiakangsi-B (01167.HK): The company received the first payment for the exclusive license agreement with shanghai allist pharmaceuticals co., ltd. on GLECIRASIB and JAB-3312, as well as partial compensation for research and development expenses and other p
Grants of September 27th, Akesi-B (01167.HK) announced an exclusive license agreement with shanghai allist pharmaceuticals co., ltd. for Glecirasib and JAB-3312. The Company's subsidiary, Beijing Akesi New Drug Development Co., Ltd. (an indirectly-held non-wholly-owned subsidiary of the Company), has received an amount of approximately RMB 0.173 billion on August 30, 2024 from shanghai allist pharmaceuticals co., ltd. for the external license agreement on KRAS G12C inhibitor Glecirasib (JAB-21822) and SHP2 variant inhibitor JAB-3312, including an initial payment.
No Data
No Data